The effectiveness of granulocyte colony-stimulating factor for treatment of non-M3 acute myelogenous leukemia patients.

Phase 1

• Conditions: on-M3 acute myelogenous leukemia patients.; Acute myelomonocytic leukemia; C92.5

• Registration Number: IRCT20211219053451N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Non-M3 acute myelogenous leukemia patients have not received treatment
Aged between 18 and 70 years

Exclusion Criteria

Secondary acute myeloid leukemia patients
Pregnant women with leukemia
Patients with other malignancies
Having cardiovascular disease
Patients with Anaphylactic shock

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Extinction of disease. Timepoint: 28 days after intervention. Method of measurement: Bone marrow biopsy.;One-year survival of patients. Timepoint: One year after intervention. Method of measurement: Questionnaire.